Results 181 to 190 of about 13,758 (226)

Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy

Anaesthesia, 2009
Summary Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is used for selected gastrointestinal carcinomas. We report a case of ventricular tachycardia during HIPEC with cisplatin that persisted as long as the chemotherapy solution remained in the intra‐abdominal cavity.
C A, Thix, I, Königsrainer, R, Kind, P, Wied, T H, Schroeder   +4 more
openaire   +2 more sources

Hyperthermic Intraoperative Intraperitoneal Chemotherapy Safety Considerations

AORN Journal, 1996
ABSTRACTPerioperative staff members encounter many occupational exposure hazards in the workplace. Cytotoxic agent exposure is a relatively new hazard that perioperative staff members are experiencing as more surgeons use hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) to treat patients with abdominopelvic cavity malignancies. Routes of
S K, White, A D, Stephens, P H, Sugarbaker   +2 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy

2017
Peritoneal metastasis in abdominal malignancies is associated with a dismal prognosis. In the past, it was considered inoperable and the patient was considered a candidate for palliative chemotherapy alone. The outcome of systemic chemotherapy is poor with the average survival being 6–8 months.
Nikhil Gupta, Shivendra Singh
openaire   +1 more source

Imaging in Hyperthermic Intraperitoneal Chemotherapy

RadioGraphics
Imaging plays an integral role in the management of patients undergoing hyperthermic intraperitoneal chemotherapy, enabling accurate patient selection, estimation of the peritoneal carcinomatosis index and completeness of cytoreduction score, and evaluation of postprocedural complications.
Shravya Srinivas Rao, Nikitha Uma Baskaran, Jinjin Cao, Onofrio A. Catalano, James A. Brink, James C. Cusack, Avinash R. Kambadakone   +6 more
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer

Journal of Obstetrics and Gynaecology Research, 2020
AbstractAimHyperthermic intraperitoneal chemotherapy (HIPEC) is a method of administering anticancer agents directly while heating the abdominal cavity. The aim of this review is to know the current position of HIPEC in ovarian cancer and uterine sarcoma and its future prospects.MethodsThis article reviews the current literature and evidence for the ...
Hideaki, Tsuyoshi, Daisuke, Inoue, Tetsuji, Kurokawa, Yoshio, Yoshida   +3 more
openaire   +2 more sources

Scrotal Ulcer After Intraperitoneal Hyperthermic Chemotherapy

Urology, 2007
Tumor cytoreduction combined with intraperitoneal hyperthermic chemotherapy has been shown to be an effective method to delay the progression of peritoneal carcinomatosis. We describe 2 cases of painful scrotal ulcer after tumor debulking and intraperitoneal infusion of mitomycin-C for treatment of metastatic abdominal malignancies.
Ardavan, Akhavan, Ming, Yin, Ronald, Benoit   +2 more
openaire   +2 more sources

Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors

Asian Journal of Endoscopic Surgery, 2020
AbstractIntroductionThe application of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal and appendix cancer at risk of peritoneal seeding is an appealing strategy to prevent peritoneal metastases. Here, we present the technical details and postoperative outcomes of laparoscopic HIPEC performed with prophylactic intent in three patients ...
Antonio Sommariva, Marco Tonello, Ottavia De Simoni, Andrea Barina, Carlo Riccardo Rossi, Pierluigi Pilati   +5 more
openaire   +2 more sources

[Hyperthermic intraperitoneal chemotherapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion.
H, Leebmann, P, Piso
openaire   +1 more source

Intraperitoneal hyperthermic chemotherapy in ovarian cancer

International Journal of Gynecological Cancer, 2005
We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB-IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles). Disease-free survival, overall survival, and side effects were compared with a control group of patients who ...
J, Gori, R, Castaño, M, Toziano, D, Häbich, J, Staringer, D G B, De Quirós, N, Felci   +6 more
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update

Hormone Molecular Biology and Clinical Investigation, 2020
Abstract In the treatment of advanced-stage epithelial ovarian cancer (EOC)-associated surgery and chemotherapy with intravenous platinum/taxane-based therapy most patients had early or late recurrence. Prevention of progression and recurrence is a major objective for the management of EOC.
Revaux, A., Carbonnel, M., Kanso, F., Naoura, I., Asmar, J., Kadhel, P., Ayoubi, J.-M.   +6 more
openaire   +3 more sources